Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access

Published:2024-02-22 Issue:6 Volume:115 Page:1204-1207
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Hong Eunjin¹^ORCID,Zampoli Marco²^ORCID,Beringer Paul M.³⁴^ORCID

Affiliation:

1. College of Pharmacy CHA University Seongnam‐si South Korea

2. Department of Paediatrics and Child Health Red Cross War Memorial Children's Hospital Cape Town South Africa

3. Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles California USA

4. USC Anton Yelchin CF Clinic Los Angeles California USA

Publisher

Wiley

Link

https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.3214

Reference10 articles.

1. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

2. Worldwide rates of diagnosis and effective treatment for cystic fibrosis

3. Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis

4. CF Foundation Urges Select Health to Cover CFTR Modulators in 2024 (2023) Accessed December 27 2023.

5. Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP